LB Pharmaceuticals completes routine annual meeting, elects three directors for 2026-2029

Filed June 9, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected three Class I directors to three-year terms through 2029: Dr. Robert Lenz (20.1M votes), Rebecca Luse (18.5M votes), and Ran Nussbaum (18.7M votes), all receiving majority support.

  Item 5.07 verify on EDGAR →
• low

  BDO USA, P.C. ratified as independent auditor for fiscal 2026 with 23.3M votes in favor, representing overwhelming stockholder approval of the accounting firm.

  Item 5.07 verify on EDGAR →